Prosensa is an innovative Dutch biopharmaceutical company focused on the discovery, development and commercialization of RNA-modulating therapeutics correcting gene expression in diseases with significant unmet need, in particular neuromuscular disorders. Prosensa's current focus is on developing treatments for Duchenne muscular dystrophy (DMD), Myotonic Dystrophy and Huntington's disease. In 2009 Prosensa entered into a strategic alliance for part of its DMD exon skipping program with GlaxoSmithKline. Prosensa's lead compound (drisapersen), being developed by GSK, is currently in late-stage phase III clinical trials. Prosensa is a privately held biopharmaceutical company, backed by a consortium of Abingworth, Gimv, Idinvest Partners, Life Sciences Partners, MedSciences Capital and New Enterprise Associates.
| Website | http://www.prosensa.com |
| Revenue | $12.2 million |
| Funding | $73.1 million |
| Employees | View employees |
| Address | 21 Jh Oortweg, Leiden, South Holland, NL |
| Phone | +31 71 332 2100 |
| Industry | Manufacturing General, Manufacturing |
| Competitors | Novartis, Bristol Myers Squibb, Solid Biosciences, Wave Life Sciences, REGENXBIO Inc., Catalyst Pharmaceuticals, Inc., Genethon, Plexxikon Inc., Akcea Therapeutics, Sarepta Therapeutics, Inc. +40 more (view full list) |
| SIC | SIC Code 67 Companies, SIC Code 671 Companies |
| NAICS | NAICS Code 55 Companies, NAICS Code 325 Companies, NAICS Code 5511 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 551 Companies |
Looking for a particular Prosensa B.V. employee's phone or email?
Prosensa B.V. Questions
The Prosensa B.V. annual revenue was $12.2 million in 2026.
Prosensa B.V. is based in Leiden, South Holland.
The NAICS codes for Prosensa B.V. are [55, 325, 5511, 32541, 32, 3254, 551].
The SIC codes for Prosensa B.V. are [67, 671].
